Studies blood samples from people with unusual HIV patterns
Tests blood samples from adults with HIV who have unusual disease patterns.
Plain-language title generated from the registry record
Registry title: the ANRS CO21 " Extreme " Cohort (CODEX)
Key facts
- Where
- Le Kremlin-Bicêtre, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT01520844, who can take part
Where in France
- LambotteLe Kremlin-Bicêtre, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- ANRS, Emerging Infectious Diseases
- Trial code
- NCT01520844
- Record updated
- 7 April 2026
- Original description
A consortium of research teams has studied the immunovirological characteristics of these patients:Read full original descriptionShow less
Multicentric Cohort of HIV Patient With Extrem Profil
A consortium of research teams has studied the immunovirological characteristics of these patients:
The ANRS CO15 ALT cohort The ANRS CO18 HIV Controller cohort the ANRS EP47 VISCONTI study
Inclusion: Patient infected with HIV-1 and not co-infected with HIV-2; Age ≥ 18 at enrollment; Able to give written consent; Covered by French Social Security; accept the constraints imposed by the study; without antiretroviral therapy for ALT, HIC and ALT HIC groups and a control of viral load after antiretroviral treatment interruption in PTC group; ALT group: Documented HIV-1 seropositive for at least 8 years with a CD4 count above 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years regardless of the viral load in the absence of antiretroviral treatment; HIC group: HIV-1 Seropositivity known for at least five years, asymptomatic, with the last 5 viral loads in HIV-RNA consecutive <400 copies / mL regardless of CD4 count in the absence of antiretroviral treatment; ALT HIC group: HIV-1 seropositive known for at least 8 years and CD4 cell counts greater than 600/mm3 with a rate stable or increasing (positive or zero slope) on at least three consecutive examinations performed during the last 5 years and with the last 5 viral loads in HIV-RNA consecutive <400 copies / mL in the absence of antiretroviral therapy; PTC group: Patients with plasma HIV RNA > 2000 copies/mL before initiation of antiretroviral therapy. Treatment started during the primary infection (as defined by symptoms associated with seroconversion, as confirmed by a first negative ELISA and/or an incomplete P24-positive Western blot) or during the chronic phase of infection, and maintained for at least 12 months in both cases. Control of viral load after antiretroviral treatment interruption: patients must have at least two available viral load assays after stopping antiretroviral therapy. All viral loads must be <400 copies/mL for 12 months or more after stopping antiretroviral therapy, with the possible exception of one blip (one viral load above 400 copies/mL between two viral loads <400 copies/mL at least one month apart from the blip; in this case at least three viral load assays will be required). The last plasma viral load value at the time of inclusion must always be <400 copies/mL.
Exclusion: Under protection(saving) of justice.